BROMOCRIPTINE - search results

apotex nz ltd - bromocriptine mesilate 5.7mg - 6mg equivalent to 5 mg bromocriptine, adjusted depending on the content of water; - capsule - 5 mg - active: bromocriptine mesilate 5.7mg - 6mg equivalent to 5 mg bromocriptine, adjusted depending on the content of water excipient: capsugel caramel g4icsa00117 lactose monohydrate maize starch opacode black s-1-8114 opacode black s-1-8115 purified talc stearic acid - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.

Singapore - English - HSA (Health Sciences Authority)

aa pharma bromocriptine tablet 2.5 mg

pharmaforte singapore pte ltd - bromocriptine mesylate eqv bromocriptine - tablet, film coated - 2.5 mg - bromocriptine mesylate eqv bromocriptine 2.5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

alpha-bromocriptine

apotex nz ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid povidone

United States - English - NLM (National Library of Medicine)

cycloset- bromocriptine mesylate tablet

santarus, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 0.8 mg - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - postpartum patients. serious and life-threatening adverse reactions have been reported with bromocriptine use in this population [see warnings and precautions (5.7), adverse reactions